
Numerous beta-lactamase inhibitors have been developed to overcome the problems of bacterial resistance to beta-lactam antibiotics. One such agent, clavulanic acid, has been combined with amoxicillin, and the combination is effective against many amoxicillin-resistant organisms. Clinical studies have demonstrated the efficacy of amoxicillin/clavulanate in a variety of infections, however, comparative studies are few and have not demonstrated sufficiently the superiority of the combination over conventional antibiotic therapy. In addition, side effects appear to be more frequent than with amoxicillin alone. The place in therapy of amoxicillin/clavulanate is discussed.
Clavulanic Acids, Sulbactam, Amoxicillin, Humans, Penicillanic Acid, Bacterial Infections, Amoxicillin-Potassium Clavulanate Combination, beta-Lactamase Inhibitors, Clavulanic Acid
Clavulanic Acids, Sulbactam, Amoxicillin, Humans, Penicillanic Acid, Bacterial Infections, Amoxicillin-Potassium Clavulanate Combination, beta-Lactamase Inhibitors, Clavulanic Acid
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 2 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
